Literature DB >> 12060564

Estradiol attenuates hypoxia-induced pulmonary endothelin-1 gene expression.

Scott Earley1, Thomas C Resta.   

Abstract

The ovarian hormone 17beta-estradiol (E2beta) attenuates chronic hypoxia-induced pulmonary hypertension. We hypothesized that E2beta attenuates this response to hypoxia by decreasing pulmonary expression of the vasoactive and mitogenic peptide endothelin-1 (ET-1). To test this hypothesis, we measured preproET-1 mRNA and ET-1 peptide levels in the lungs of adult female normoxic and hypoxic (24 h or 4 wk at barometric pressure = 380 mmHg) rats with intact ovaries and in hypoxic ovariectomized (OVX) rats administered E2beta or vehicle via subcutaneous osmotic pumps. Hypoxic exposure increased lung preproET-1 mRNA levels in OVX vehicle-treated rats, but not in rats with intact ovaries. In addition, E2beta replacement prevented hypoxia-mediated increases in preproET-1 mRNA and ET-1 peptide expression. Considering that hypoxic induction of ET-1 gene expression is mediated by a hypoxia-inducible transcription factor(s) (HIF), we further hypothesized that E2beta-induced attenuation of pulmonary ET-1 expression during hypoxia results from decreased HIF activity. We found that E2beta abolished HIF-dependent increases in reporter gene activity. Further experiments demonstrated that overexpression of the transcriptional coactivator cAMP response element binding protein (CREB) binding protein (CBP)/p300, a factor common to both the estrogen receptor and HIF pathways, eliminated E2beta-mediated attenuation of hypoxia-induced ET-1 promoter activity. We conclude that E2beta inhibits hypoxic induction of ET-1 gene expression by interfering with HIF activity, possibly through competition for limiting quantities of CBP/p300.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12060564     DOI: 10.1152/ajplung.00476.2001

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  27 in total

1.  17β-estradiol protects the lung against acute injury: possible mediation by vasoactive intestinal polypeptide.

Authors:  Sayyed A Hamidi; Kathleen G Dickman; Hasan Berisha; Sami I Said
Journal:  Endocrinology       Date:  2011-10-18       Impact factor: 4.736

2.  Pulmonary hypertension: a woman's disease.

Authors:  Zeenat Safdar
Journal:  Tex Heart Inst J       Date:  2013

3.  Let's Talk about Sex: A Novel Mechanism by Which Estrogen Receptor β Limits Hypoxia-Inducible Factor Expression in Pulmonary Endothelial Cells.

Authors:  Larissa A Shimoda
Journal:  Am J Respir Cell Mol Biol       Date:  2018-07       Impact factor: 6.914

Review 4.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

5.  The sexual dimorphism associated with pulmonary hypertension corresponds to a fibrotic phenotype.

Authors:  Olga Rafikova; Ruslan Rafikov; Mary Louise Meadows; Archana Kangath; Danny Jonigk; Stephen M Black
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

6.  17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects.

Authors:  Tim Lahm; Marjorie Albrecht; Amanda J Fisher; Mona Selej; Neel G Patel; Jordan A Brown; Matthew J Justice; M Beth Brown; Mary Van Demark; Kevin M Trulock; Dino Dieudonne; Jagadeshwar G Reddy; Robert G Presson; Irina Petrache
Journal:  Am J Respir Crit Care Med       Date:  2012-03-01       Impact factor: 21.405

Review 7.  Sex differences and sex steroids in lung health and disease.

Authors:  Elizabeth A Townsend; Virginia M Miller; Y S Prakash
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

8.  Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.

Authors:  Revathi Rajkumar; Kazuhisa Konishi; Thomas J Richards; David C Ishizawar; Andrew C Wiechert; Naftali Kaminski; Ferhaan Ahmad
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-15       Impact factor: 4.733

9.  Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Robert S Brown; James F Trotter; Inga Peter; Hocine Tighiouart; James A Knowles; Daniel Rabinowitz; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2009-02-12       Impact factor: 21.405

10.  NFATc3 is required for intermittent hypoxia-induced hypertension.

Authors:  Sergio de Frutos; Laura Duling; Dominique Alò; Tammy Berry; Olan Jackson-Weaver; Mary Walker; Nancy Kanagy; Laura González Bosc
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-03-21       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.